Article from Kings College of London News Centre

By Adrian Hayday, Professor of Immunobiology

 “More than half of cancer patients receiving a single dose of the Pfizer COVID-19 vaccine have been left with little protection against the virus.

Data from the world’s first reported trial to examine the level of immune protection after the Pfizer-BioNTech vaccine in cancer patients has found that anti-SARS-CoV-2 antibody responses at week 3 following the first dose of the vaccine were only 39% and 13% in the solid and haematological cancers, compared to 97% in those without cancer. ”

Continue reading the full article: Delaying 2nd vax dose leaves cancer patients vulnerable to virus



Submit a Comment